What is UroGen Pharma's market cap?

UroGen Pharma (URGN) has a market capitalization of $2.0B and trades on NASDAQ.

What is UroGen Pharma's revenue and profitability?

UroGen Pharma generated $140.5M in trailing twelve-month revenue with a net loss of $133.2M, representing a net margin of -94.8%. Gross margin stands at 89.7%, with free cash flow of -$166.0M. These figures are based on the Q1 2026 filing.

Who are UroGen Pharma's competitors?

UroGen Pharma's key competitors include Merck & Co., Inc., ImmunityBio, Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.

Who does UroGen Pharma partner with?

UroGen Pharma's notable partners include medac Gesellschaft für klinische Spezialpräparate m.b.H., IconOVir Bio, Inc., Agenus Inc..

What subsidiaries does UroGen Pharma have?

UroGen Pharma's subsidiaries include UroGen Pharma, Inc..

Where is UroGen Pharma headquartered?

UroGen Pharma is headquartered in United States of America and employs approximately 204 people. It has been publicly traded since 2017.

UroGen Pharma

URGN

UroGen Pharma is a commercial-stage biotechnology company focused on developing and commercializing novel solutions for urothelial and specialty cancers.

Market cap

$2.02B+127%

Revenue$140.5M+52.9%

Net income-$133.2M+3.8%

Free cash flow-$166.0M-54.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$51.0MBeat by $6.1M EPS-$0.47Beat by $0.09

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$63.5M

EPS estimate-$0.27

Financials

Q1 2026

Income statement

See full

Revenue$51.0M+152%

Net income-$23.6M+46.2%

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation & ratios

Valuation

See full

Market cap$2.02B+127%

Enterprise value$2.11B+132%

P/S14.4×+5.1×

Profitability

See full

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Current ratio4.7×-1.0×

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Merck & Co.$322.95B+53.0%

Pfizer$140.61B+1.7%

Bristol-Myers Squibb$127.75B+32.1%

ImmunityBio, Inc.$7.3B+213%

UroGen Pharma$2.0B+131%

Relmada Therapeutics, Inc.$545.9M+2,468%

Unicycive Therapeutics, Inc.$140.5M+134%

By revenue growth

ImmunityBio, Inc.+352%

UroGen Pharma+52.9%

Johnson & Johnson+8.1%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

Pfizer+1.4%

By net margin

Johnson & Johnson21.48%-3.5pp

Pfizer15.65%+6.3pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

UroGen Pharma-94.83%+55.8pp

ImmunityBio, Inc.-606.15%+704pp

Profile

UroGen Pharma is a commercial-stage biotechnology company focused on developing and commercializing novel solutions for urothelial and specialty cancers. The company utilizes its proprietary RTGel reverse-thermal hydrogel technology to improve the therapeutic profiles of existing drugs by enabling sustained release and longer exposure of medications to urinary tract tissue. Its primary value proposition lies in providing non-surgical chemoablation alternatives to repetitive and burdensome surgical procedures.

Competitive position

A pioneer in non-surgical chemoablation for low-grade UTUC and NMIBC, holding the first FDA-approved treatments for these specific indications.

GeographiesUnited States, Israel

Customer segmentsHealthcare Providers, Specialty Pharmacies

Business modelProduct-based, R&D intensive

SuppliersContract Manufacturing Organizations (CMOs), Raw material suppliers, Active Pharmaceutical Ingredient (API) suppliers

CustomersSpecialty pharmacies, Mixing pharmacies, Hospitals, Urology clinics

CountryUnited States of America

Listed2017

Employees204.0

CEOElizabeth Barrett

SectorHealthcare

IndustryBiotechnology

Websiteurogen.com

FilingsSEC EDGAR

Ask your AI about UroGen Pharma.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's market cap?: UroGen Pharma (URGN) has a market capitalization of $2.0B and trades on NASDAQ.
What is UroGen Pharma's revenue and profitability?: UroGen Pharma generated $140.5M in trailing twelve-month revenue with a net loss of $133.2M, representing a net margin of -94.8%. Gross margin stands at 89.7%, with free cash flow of -$166.0M. These figures are based on the Q1 2026 filing.
Who are UroGen Pharma's competitors?: UroGen Pharma's key competitors include Merck & Co., Inc., ImmunityBio, Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
Who does UroGen Pharma partner with?: UroGen Pharma's notable partners include medac Gesellschaft für klinische Spezialpräparate m.b.H., IconOVir Bio, Inc., Agenus Inc..
What subsidiaries does UroGen Pharma have?: UroGen Pharma's subsidiaries include UroGen Pharma, Inc..
Where is UroGen Pharma headquartered?: UroGen Pharma is headquartered in United States of America and employs approximately 204 people. It has been publicly traded since 2017.